CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from Brokerages

Shares of CareDx, Inc. (NASDAQ:CDNA - Get Free Report) have been given a consensus recommendation of "Hold" by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $26.6667.Several analysts have weighed in on the stock. William Blair initiated coverage on shares of CareDx in a research note on Tuesday, August 26th. They set a "market perform" rating for the company. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of CareDx in a report on Monday, December 15th. Wells Fargo & Company increased their price objective on shares of CareDx from $14.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Monday, December 15th. Zacks Research raised CareDx from a "strong sell" rating to a "hold" rating in a report on Tuesday, November 18th. Finally, Wall Street Zen upgraded CareDx from a "hold" rating to a "buy" rating in a research report on Sunday.Get Our Latest Stock Report on CareDxHedge Funds Weigh In On CareDxSeveral hedge funds and other institutional investors have recently modified their holdings of CDNA. Bamco Inc. NY increased its holdings in shares of CareDx by 29.5% in the 3rd quarter. Bamco Inc. NY now owns 3,155,180 shares of the company's stock worth $45,876,000 after acquiring an additional 719,523 shares during the period. Deerfield Management Company L.P. acquired a new position in CareDx during the 3rd quarter valued at about $31,857,000. Braidwell LP bought a new position in CareDx in the 3rd quarter worth about $31,738,000. ARK Investment Management LLC increased its stake in shares of CareDx by 3.4% in the third quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company's stock valued at $31,561,000 after purchasing an additional 70,468 shares during the period. Finally, Ophir Asset Management Pty Ltd raised its holdings in shares of CareDx by 17.0% during the second quarter. Ophir Asset Management Pty Ltd now owns 1,892,994 shares of the company's stock valued at $36,989,000 after buying an additional 274,625 shares during the last quarter. CareDx Stock PerformanceShares of CareDx stock opened at $19.45 on Monday. CareDx has a 1 year low of $10.96 and a 1 year high of $25.95. The firm's 50-day simple moving average is $16.69 and its 200-day simple moving average is $15.81. The firm has a market cap of $1.00 billion, a PE ratio of 16.34 and a beta of 2.54. CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.15. The firm had revenue of $100.06 million for the quarter, compared to analysts' expectations of $95.25 million. CareDx had a return on equity of 20.15% and a net margin of 19.65%.CareDx's revenue for the quarter was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. On average, equities analysts predict that CareDx will post -0.9 earnings per share for the current year. About CareDx (Get Free Report)CareDx, Inc NASDAQ: CDNA is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey. The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.Recommended StoriesFive stocks we like better than CareDxHow Long Will $1M Last in Retirement?GOLD ALERTBitcoin is down but your income is about to explodeThis 40-year cover-up is endingHow the Rich RetireThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in CareDx Right Now?Before you consider CareDx, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.While CareDx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here